4 hours Clover Health Investments (NASDAQ:CLOV) Earns Neutral Rating from Analysts at UBS Group MarketBeat
UBS Group initiated coverage on Clover Health Investments in a research report on Monday. They issued a “neutral” rating and a $4.00 price objective on the stock.
Health · Nasdaq 100 · Science